Jones T

No ORCID on file · 5 papers in corpus · active 2018-2023

Study types

  • article 2

Condition tags

  • endometriosis 2
  • dysmenorrhea 1
2023
Quantifying the Impact of Dysmenorrhea Symptoms on Quality-of-Life and Access to Oral Contraceptives by Income.
Health psychology research ·doi:10.52965/001c.74120

BackgroundDysmenorrhea, or painful menstrual periods, is one of the most common gynecological complaints. Most reports of uterine contractions range between moderate to severe pain, and patients often elect to cope with their discomfort wit…

2021
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
Cancers ·doi:10.3390/cancers13153854

Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian cancer characterised by a high frequency of loss-of-function ARID1A mutations and a poor response to chemotherapy. Despite their generally low mutational burden, an…

article 2020
MRI impacts endometriosis management in the setting of image-based multidisciplinary conference: a retrospective analysis
Abdominal radiology (New York) ·doi:10.1007/s00261-020-02417-6

PurposeThe aim of the study was to quantify the value of pre-operative magnetic resonance imaging (MRI) in guiding surgical management of women with endometriosis.MethodsPre-operative discussion of patient management and review of imaging o…

article 2019
Association between kissing and retropositioned ovaries and severity of endometriosis: MR imaging evaluation
Abdominal radiology (New York) ·doi:10.1007/s00261-019-02153-6

PurposeTo retrospectively investigate the relationship between ovarian positioning on pre-operative MR imaging and intra-operative staging of endometriosis.Materials and methodsSixty-five women with suspected endometriosis who underwent pre…

2018
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
The journal of pathology. Clinical research ·doi:10.1002/cjp2.103

ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ARID1A defects. How…